UCB : Transparency notifications

Brussels (Belgium), 8 September 2016 - 20:00 (CEST) - regulated information

1. Summary of the notifications

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency notifications from Wellington Management Group LLP (having its registered offices at 280 Congress Street, Boston, MA 02110, USA), dated 5 and 6 September 2016 respectively.

In the first notification, Wellington Management Group LLP informed that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV had decreased and had crossed downward the 3% threshold on 1 September 2016. In the second notification, Wellington Management Group LLP notified that it crossed the 3% minimum threshold again, following an acquisition of UCB shares with voting rights by its affiliates on 2 September 2016.

On 1 September 2016, Wellington Management Group LLP (taking into account the holding of its affiliates) owned 5 811 663 UCB shares with voting rights (versus 5 872 320 UCB shares in its previous notification on 12 August 2016), representing 2.99% of the total number of shares issued by the company (194 505 658) (3.02% on 12 August 2016).

On 2 September 2016, Wellington Management Group LLP (taking into account the holding of its affiliates) announced that it owned 5 839 746 UCB shares with voting rights, representing 3.00% of the total number of shares issued by the company.

2. Content of the notifications

The transparency notification dated 5 September 2016 included the following information:

• Reason for the notification:
  • Acquisition or disposal of voting securities or voting rights;
  • Downward crossing of the lowest threshold.
• Date on which the threshold is crossed: 1 September 2016.
• Threshold crossed (in %): 3%.
• Notified details:

The transparency notification dated 6 September 2016 included the following information:

• Reason for the notification: Acquisition or disposal of voting securities or voting rights.
• Date on which the threshold is crossed: 2 September 2016.
• Threshold crossed (in %): 3%.
• Notified details:

The information mentioned hereafter was identical in both notifications:

• Notification by: A parent undertaking or a controlling person.
• Person subject to the notification requirement: Wellington Management Group LLP, 280 Congress Street, Boston, MA 02110, USA
• Denominator: 194 505 658.
• Chain of controlled undertakings through which the holding is effectively held:

Wellington Management Company LLP is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.

Wellington Management International Ltd, is a direct controlled undertaking of Wellington Management Global Holdings, Ltd, which, in turn, is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.

Wellington Management Company LLP is an investment management company and can exercise the voting rights at its discretion in the absence of specific instructions from the beneficial owners of the shares.
Wellington Management International Ltd is an investment management company and can exercise the voting rights at its discretion in the absence of specific instructions from the beneficial owners of the shares.

3. Further information

This press release and the detailed transparency notifications are available on UCB SA/NV's website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be included in the corporate governance charter of UCB SA/NV, which is available on its website via the following link.

Investor Relations
Antje Witte
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news